Basilea Valuation Report update "A moving year ahead"

Monday, April 11, 2022 @ 12:00 am

FY 2021 results exceeded guidance, reflecting strong Cresemba growth, resulting in an operating profit. Basilea will focus on anti-infectives and accelerate its path to sustained profitability guided from 2023 onwards. Oncology will be exited through asset transactions in 2022. Key catalysts include:

Strategic transactions oncology pipeline (during 2022)
Topline results phase III “ERADICATE” trial of Zevtera in bacteremia (mid-2022)
US filing of Zevtera for severe bacterial infections (H2 2022)

Read the full Basilea Valuation Report

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

Bioversys receives USD 6 million from Guangzhou Sino-Israel Bio-Industry Investment Fund

GIBF2 to invest US$ 6m in BioVersys BV100 Phase 1 study in China expected to start in 1H 2025 in preparation for a global Phase 3 registrational study
September 11, 2024

ABCDX: Heart-type fatty acid binding protein as biomarker for Transient Ischemic Attack

ABCDx, a leader in brain injury diagnostics, is proud to announce the acceptance of the article, "Heart-type fatty acid binding protein as a biomarker in transient ischemic attack," for publication in the prestigious journal, Cardiovascular Translational Research. This pivotal study highlights the innovative use of Heart-type Fatty Acid Binding Protein (H-FABP) as a diagnostic biomarker for Transi
September 9, 2024

Boehringer Ingelheim and CDR-Life advance treatment for Geographic Atrophy

Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record | ClinicalTrials.gov), an investigational antibody fragment developed to preserve vision in people living with geographic atrophy (GA). BI 771716 met its primary safety endpoint following intravitreal administration of single and multiple doses. Preparation for the Phase II tria
September 5, 2024

HAYA Therapeutics: Collaboration with Eli Lilly to target obesity and related metabolic conditions

HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
September 4, 2024

AlphaMol discovered new molecular mechanism for anti-depression drug target

The 5-HT3 receptor (5-HT3R) is a member of the Cys-loop family of ligand-gated ion channels, which are in both the peripheral and central nervous systems. 5-HT3R is involved in regulation of neurotransmitter systems implicated in the pathophysiology of major depression. In this work, AlphaMol collaborated with Max Planck Institute, discovered that different from traditional homopentamer, 5-TH3R co
September 4, 2024